Detoxification of Opiate Addicts with Multiple Drug Abuse: a Comparison of Buprenorphine vs. Methadone

Over the last few years, there has been a growing tendency for opioid addicts to abuse multiple drugs, although many patients are in substitution therapy with methadone. Abuse of multiple drugs leads to a more complicated withdrawal syndrome; it is therefore necessary to investigate new drug strategies as a treatment for detoxification. Buprenorphine appears to be an effective and safe drug in opioid-addicted patient detoxification. In this study, we have compared the short-term efficacy of an 11-day low-dose buprenorphine/14-day carbamazepine regime [BPN/CBZ] (n = 14) to an 11-day methadone/14-day carbamazepine regime [MET/CBZ] (n = 12) in a double-dummy, randomized 14-day inpatient detoxification treatment study. Twenty-six inpatients met the DSM-IV criteria for opioid dependence and were included in this study. All patients abused various additional drugs. Fourteen of 26 patients (53.8 %) completed the study. Seven non-completers (seven of 12 = 58.3 %) were treated with methadone/carbamazepine and five non-completers (five of 14 = 35.7 %) received buprenorphine/carbamazepine, but the difference in the dropout rate was not significant. However, patients with buprenorphine/carbamazepine showed significantly fewer withdrawal symptoms after the first two weeks of treatment. The present study supports the hypothesis that buprenorphine/carbamazepine is more effective than methadone/carbamazepine in detoxification strategies for opioid addict with additional multiple drug abuse. No severe side effects occurred during treatment in either group.

References

• 1 Amass L, Bickel W K, Higgins S T, Badger G J. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification.  J Addict Dis. 1994;  13 33-45
• 2 Banys P, Ckark H W, Tusel D J, Sess K, Stewart P, Mongan L, Delucchi K, Callaway E. An open trial of low dose buprenorphine in treating methadonse withdrawal.  J Subst Abuse Treat. 1994;  11 9-15
• 3 Bertschy G, Bryois C, Bondolfi G. The association carbamazepine-mianserin in opiate withdrawal. a double blind pilot study versus clonidine.  Pharmacol Res. 1997;  35 451-456
• 4 Bouchez J, Beuverie P, Touzeau D. Substitution with buprenorphine in methadone- and morphine sulfate-dependent patients. Preliminary results.  Eur Addict Res. 1998;  4 (suppl 1) 8-12
• 5 Cowan A, Lewis J W, Macfarlane I R. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.  Br J Pharmacol. 1977;  60 537-545
• 6 Cowan A, Lewis J W. Laboratory studies of Buprenorphine in opioid abusers. In: Buprenorphine 1995: 200-204
• 7 Darke S, Hall W. Levels and correlates of polydrug use among heroin users and regular amphetamine users.  Drug Alcohol Depend. 1995;  39 31-35
• 8 Dum J, Bläsig J, Herz A. Buprenorphine: demonstration of physical dependence liability.  Eur J Pharmacol. 1981;  70 293-300
• 9 Eder H, Fischer G, Gombas W, Jagsch R, Stuhlinger G, Kasper S. Comparison of buprenorphine and methadone maintenance in opiate addicts.  Eur Addict Res. 1998;  4 (Suppl 1) 3-7
• 10 Emrich H M, Dose M, Wolf R. The action of mood-stabilizers in affective disorders: an integrative view as a challenge.  Neuropsychobiol. 1993;  27 158-162
• 11 Fudala P J, Jaffe J H, Dax E M, Johnson R E. Use of buprenorphine in the treatment of opioid addiction. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal.  Clin Pharmacol Ther. 1990;  47 525-534
• 12 Garcia-Borreguero D, Bronisch T, Apelt S, Yassouridis A, Emrich H M. Treatment of benzodiazepine withdrawal symptoms with carbamazepine.  Eur Arch Psychiatr Clin Neurosci. 1991;  241 145-150
• 13 Gossop M. The development of a short opiate withdrawal scale (SOWS).  Addict Behav. 1990;  15 487-490
• 14 Halikas J A, Crosby D, Pearson V L, Graves N M. A randomized double-blind study of carbamazepine in the treatment of cocaine abuse.  Clin Pharmacol Ther. 1997;  62 89-105
• 15 Heel R C, Brogden R N, Speight T M, Avery G S. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy.  Drugs. 1979;  17 81-110
• 16 Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing?.  Statistics in Medicine. 1990;  9 811-818
• 17 Holladay J W, Tortella F C, Belenky G L. EIectroconvulsive shock (ECS) results in a functional activation of endorphin Systems. In: Emrich HM, editor The Role of Endorphins in Neuropsychiatry. Karger Basel; 1981: p. 142-157
• 18 Jasinski D R, Pevnick J S, Griffith J D. Human pharmacology and abuse potential of the analgesic buprenorphine.  Arch Gen Psychiatry. 1978;  35 501-516
• 19 Johnson R E, Cone E J, Henningfield J E, Fudala P J. Use of buprenorphine in the treatment of opiate addiction. Physiological and behavioral effects during a rapid dose induction.  Clin Pharmacol Ther. 1989;  46 335-343
• 20 Johnson R E, Jaffe J H, Fuldala P J. A controlled trial of buprenorphine treatment for opioid dependence.  J Am Med Assoc. 1991;  67 2750-2755
• 21 Kasvikis Y, Bradley B, Gossop M, Griffiths P, Marks I. Clonidine versus long- and short-term methadone-aided withdrawal from opiates. An uncontrolled comparison.  Int J Addict. 1990;  25 1169-1178
• 22 Kosten T R, Kleber H D. Buprenorphine detoxification from opioid dependence. a pilot study.  Life Sci. 1988;  42 635-641
• 23 Kosten T R, Morgan C, Kleber H D. Treatment of heroin addicts using buprenorphine.  Am J Drug Alcohol Abuse. 1991;  17 119-128
• 24 Kuhlmann J J, Levine B, Johnson R E, Fudala P J, Cone E J. Relationship of plasma buprenorphine an norbuprenorphine to withdrawal symptoms during dose induction, maintance and witdrawal from sublingual buprenprphine.  Addiction. 1998;  93 549-559
• 25 Law F D, Bailey J E, Allen D S, Melichar J S, Myles M C. et al . The feasibility of abrupt methadone-buprenorphine transfer in British opiate addicts in an outpatient setting.  Addiction Biol. 1997;  2 191-200
• 26 Leander J D. Buprenorphine has potent kappa opioid receptor antagonist activity.  Neuropsychopharmacology. 1987;  26 1445-1447
• 27 Levin F R, Fischman M W, Connerney I, Foltin R. A Protocol to switch high dose methadone-maintained subjects to buprenorphine.  Am J Addict. 1997;  6 105-116
• 28 Malcolm R, Ballenger J C, Sturgis E T, Anton R. Double blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal.  Am J Psychiatry. 1989;  146 617-621
• 29 Märkl A. Rauschgiftlage 1996. In: Hüllinghorst R, Merfert-Diete C, Lindemann F, editors Jahrbuch Sucht 1998. Geesthacht: Neuland Verlag 1997: p. 67-82
• 30 Martin W R, Eades C G, Thompson J A, Huppler R E, Gilbert P E. The effects of morphine and nalorphine-like drugs in nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976: 517-532
• 31 Mattick R P, Hall W. Are detoxification programs effective?.  Lancet. 1996;  47 97-100
• 32 McCarthy P S, Howlett G J. Physical dependence induced by opiate partial agonists in the rat.  Neuropeptides. 1984;  5 233-247
• 33 Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, Watanabe M. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: A double-blind controlled study.  Psychopharmacology. 1979;  66 211-217
• 34 Pini L A, Sterieri E, Ferretti C. Dapiprazole compared with clonidine and a placebo in detoxification of opiate addicts.  Int J Pharmacol Res. 1991;  1 99-105
• 35 Placidi G F, Lenzi A, Lazzerini F, Cassano G B, Akiskal H S. The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double-blind 3-year trial in 83 patients.  J Clin Psychiatry. 1986;  47 490-494
• 36 Post R M, Weiss S RB. Kindling Implications for the course and treatment of affective disorders In: Modigh K, Roback OH, Vestergaard P, editors Anticonvulsants in Psychiatry. Wrightson Biomedical Publishing Ltd; 1994: p. 113-137
• 37 Schneider U, Paetzold W, Eronat V, Huber T, Seifert J, Wiese B, Emrich H M. Buprenorphine and carbamazepine as a treatment for detoxification of opiate addicts with multiple drug misuse: a pilot study.  Addict Biol. 2000;  5 65-69
• 38 Schweizer E, Rickels K, Case W G, Greenblat D J. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and outcome.  Arch Gen Psychiatrv. 1991;  48 448-452
• 39 Senay E C. Methadone maintenance treatment.  Int J Addict. 1985;  20 803-821
• 40 Soew S S, Quingley A J, Ilett K F, Dusci L J, Swensen G, Harrison-Stewwart A, Rappeport L. Buprenorphine a new maintenance opiate?.  Med J Aust. 1986;  144 407-411
• 41 Strain E C, Preston K L, Liebson I A, Bigelow G E. Acute effects of buprenorphine,hydromorphine and naloxone in methadone-maintained volunteers.  Journal Subst Abuse Treat. 1994;  11 9-15
• 42 Uehlinger C, Deglon J, Livoti S, Petitjean S, Waldvogel D, Ladewig D. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Swiss multicenter study.  Eur Addict Res. 1998;  4 (Suppl 1) 13-18
• 43 Walsh S L, June H L, Schuh K J, Preston K L, Bigelow G E, Stitzer M L. Effects of buprenorphine and methadone in methadone-maintained subjects.  Psychopharmacology. 1995;  119 268-276
• 44 Ward J, Hall W, Mattick R P. Role of maintenance treatment in opioid dependence.  Lancet. 1999;  353 221-226
• 45 Wolf K. Steady-State Pharmacocinetics of Methadone in Opioid Addicts.  Clin Pharmacol. 1993;  44 189